Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer
Memo - Magazine of European Medical Oncology, Volume 6, No. 2, Year 2013
Notification
URL copied to clipboard!
Description
Purpose: Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer. Recommendations: Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient's general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy. © 2013 Springer-Verlag Wien.
Authors & Co-Authors
Hilbe, Wolfgang
Austria, Innsbruck
Medizinische Universitat Innsbruck
Abacioglu, Ufuk
Turkey, Istanbul
Clinic of Radiation Oncology
Aebersold, Daniel M.
Switzerland, Bern
University Hospital Bern
Bachouchi, Mounir
Morocco, Agdal Rabat
Centre D'oncologie 16 Novembre
Brodowicz, Thomas
Austria, Vienna
Medizinische Universität Wien
Gaafar, Rabab Mohamed
Egypt, Giza
Cairo University
Holzer, Gerold
Austria, Vienna
Medizinische Universität Wien
Mohn-Staudner, Andrea
Austria, Vienna
Wiener Krankenanstaltenverbund
Kalev, Dimitar
Bulgaria
Multiprofile Hospital for Active Treatment Varna
Kalinka-Warzocha, Ewa
Poland, Lodz
Regional Cancer Center
Kovac, Viljem
Slovenia, Ljubljana
Onkološki Inštitut Ljubljana
Siano, Marco
Switzerland, St Gallen
Kantonsspital St.gallen
Yumuk, Perran Fulden
Turkey, Istanbul
Marmara Üniversitesi Tip Fakültesi
Tamasi, Lilla
Austria, Innsbruck
Medizinische Universitat Innsbruck
Hungary, Budapest
Semmelweis Egyetem
Statistics
Citations: 14
Authors: 14
Affiliations: 13
Identifiers
Doi:
10.1007/s12254-013-0088-6
ISSN:
18655041
e-ISSN:
18655076
Research Areas
Cancer
Health System And Policy